|
EMA Q&A Appendix 1 update posted on 13 March 2026
|
|
1
|
411
|
March 16, 2026
|
|
Challenges in developing an analytical method for N‑nitroso‑ambroxol -
|
|
1
|
145
|
March 14, 2026
|
|
Testing of N-nitroso-cinacalcet
|
|
8
|
1005
|
March 14, 2026
|
|
Limit Test for NDSRI Risk Assessment?
|
|
3
|
180
|
March 13, 2026
|
|
N-Nitroso Metamizole Impurity C
|
|
3
|
260
|
March 12, 2026
|
|
Navigating the complexities in characterization of NDSRIs using advanced analytical techniques-Pub
|
|
2
|
235
|
March 12, 2026
|
|
Challenges in developing an analytical method for N‑nitroso‑ambroxol
|
|
3
|
206
|
March 11, 2026
|
|
Register for Free Webinar- Australia and New Zealand: Nitrosamines Impurities 19 March 2026
|
|
0
|
214
|
March 10, 2026
|
|
Register for Quality Hour- Japan Edition: Nitrosamines Impurities 18 March 2026
|
|
0
|
210
|
March 8, 2026
|
|
N-nitroso-Duloxetine recall back in the news!
|
|
21
|
4727
|
March 7, 2026
|
|
Nitrosamine analysis in suspension dosage forms
|
|
5
|
256
|
March 6, 2026
|
|
Nitrosamine Risk in Trospium chloride tablets
|
|
2
|
156
|
March 4, 2026
|
|
The Bench Mark dose (BMD) - Recorded full two day training FREE
|
|
4
|
372
|
March 4, 2026
|
|
🇯🇵 Current Nitrosamine Landscape in Japan?
|
|
183
|
16982
|
March 1, 2026
|
|
Chat GPT's answer about the risk assessment of nitrosamine in pharmaceuticals
|
|
33
|
3961
|
February 28, 2026
|
|
Question about N-Nitroso nicardipine
|
|
5
|
781
|
February 28, 2026
|
|
N-Nitrosodibenzylamine infusion bags
|
|
0
|
115
|
February 27, 2026
|
|
Moxonidine Nitrosamines
|
|
6
|
273
|
February 25, 2026
|
|
Podcast: Reducing Nitrosamines and Driving Patient Safety
|
|
0
|
139
|
February 23, 2026
|
|
NDSRI growth with respect to age
|
|
11
|
414
|
February 23, 2026
|
|
Nitrosamine Risk Assessment on DETA
|
|
0
|
136
|
February 22, 2026
|
|
EMA proposes GMP update to EudraLex to address nitrosamine impurities
|
|
14
|
1070
|
February 20, 2026
|
|
Nitrites/Nitrosamines: The impacts on analytics, but not only
|
|
0
|
181
|
February 17, 2026
|
|
Calculation of Maximum Daily Dose (MDD) for 2 Strengths
|
|
5
|
298
|
February 17, 2026
|
|
Advantages and limitations of the inclusion of ascorbic acid on nitrosamine mitigation in pharmaceutical drug products-Pub
|
|
5
|
453
|
February 17, 2026
|
|
N-Nitroso methylphenidate anybody?
|
|
1
|
198
|
February 12, 2026
|
|
N-Nitroso Imidazole content in Clotrimazole
|
|
9
|
612
|
February 9, 2026
|
|
👨💻 Quantitation of N-Nitrosodimethylamine (NDMA) and N-Nitrosophenylephrine (NNPE) in Phenylephrine Hydrochloride (API) by LC-MS/MS
|
|
0
|
328
|
February 7, 2026
|
|
👨💻 N-Nitroso-Propranolol Test Method & Validation Report
|
|
0
|
148
|
February 7, 2026
|
|
👨💻 N-Nitroso-Methylphenidate Test Method and Validation Report
|
|
0
|
134
|
February 7, 2026
|